AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12547542 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant factor VIIa 20 microg/kg
Number of subjects: 36
Study 12547542 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant factor VIIa 40 microg/kg
Number of subjects: 36
Study 12547542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 12547542 — intervention group
Group type: COMPARATOR
Intervention: Recombinant factor VIIa vs Control
Number of subjects: 36
Study 10373275 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater relative right-sided activation
Number of subjects: 0
Study 10373275 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater relative left-sided activation
Number of subjects: 0
Study 8558217 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC2
Number of subjects: 759
Study 8558217 — intervention group
Group type: COMPARATOR
Intervention: CMF2
Number of subjects: 759
Study 8558217 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC1
Number of subjects: 759
Study 8558217 — intervention group
Group type: COMPARATOR
Intervention: CMF1
Number of subjects: 759
Study 8558217 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC (epirubicin-containing regimen)
Number of subjects: 759
Study 1829757 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (OND)
Number of subjects: 102
Study 1829757 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (OND) plus Dexamethasone (DEX)
Number of subjects: 102
Study 1829757 — intervention group
Group type: EXPERIMENTAL
Intervention: OND plus DEX
Number of subjects: 102
Study 1829757 — intervention group
Group type: COMPARATOR
Intervention: OND
Number of subjects: 102
Study 7100223 — intervention group
Group type: EXPERIMENTAL
Intervention: (-)eburnamonine (100 mg infusion)
Number of subjects: 20
Study 7100223 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic treatment with (-)eburnamonine (oral route)
Number of subjects: 20
Study 7100223 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 20
Study 31205166 — intervention group
Group type: EXPERIMENTAL
Intervention: PROMIS health domains
Number of subjects: 439
Study 31205166 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Utility Estimation Equation (HEE) derived from PROMIS domains
Number of subjects: 439
Study 31205166 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation cohort mean health utility
Number of subjects: 439
Study 29808970 — intervention group
Group type: EXPERIMENTAL
Intervention: Singing groups
Number of subjects: 0
Study 29808970 — intervention group
Group type: COMPARATOR
Intervention: Control group (wait-list)
Number of subjects: 0
Study 26260492 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated health protection/health promotion group (HP/HP)
Number of subjects: 54
Study 26260492 — intervention group
Group type: COMPARATOR
Intervention: Health protection-only group (HPO)
Number of subjects: 54
Study 24787266 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IP)
Number of subjects: 100
Study 24787266 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ischemic preconditioning)
Number of subjects: 100
Study 22895140 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan/cisplatin (TP)
Number of subjects: 795
Study 22895140 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin/etoposide (PE)
Number of subjects: 795
Study 22895140 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan/etoposide (TE)
Number of subjects: 795
Study 20015193 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent Training (PT)
Number of subjects: 99
Study 20015193 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Parent Training and Child Treatment (PT+CT)
Number of subjects: 99
Study 18061705 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol 400 mcg every 3 h
Number of subjects: 228
Study 18061705 — intervention group
Group type: COMPARATOR
Intervention: Hypertonic saline and d-cloprostenol 2.5 mg/h
Number of subjects: 228
Study 14769088 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face communication media
Number of subjects: 400
Study 14769088 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone communication media
Number of subjects: 400
Study 14769088 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer mediated communication
Number of subjects: 400
Study 14769088 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-ratings and partner ratings
Number of subjects: 400
Study 11401178 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cilomilast 1, 2, and 4 mg
Number of subjects: 96
Study 11401178 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cilomilast 15 mg
Number of subjects: 96
Study 11401178 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cilomilast 15 mg in fed subjects
Number of subjects: 96
Study 11401178 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cilomilast 15 mg in fasted subjects
Number of subjects: 96
Study 11401178 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cilomilast 15 mg with different dosing times
Number of subjects: 96
Study 11401178 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cilomilast 15 mg with aluminum hydroxide‐magnesium hydroxide
Number of subjects: 96
Study 9566385 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen-replacement therapy
Number of subjects: 2816
Study 7816217 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Back Program presentation
Number of subjects: 3430
Study 7816217 — intervention group
Group type: COMPARATOR
Intervention: Control (no presentation)
Number of subjects: 3430
Study 3190163 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate dose of vitamin C (200 mg/day)
Number of subjects: 27
Study 3190163 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of vitamin C (2,000 mg/day)
Number of subjects: 27
Study 3190163 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 1230395 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical hypnosis in group suggestive sessions and self-induced trance states
Number of subjects: 20
Study 1230395 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving standard haematologic care
Number of subjects: 20
Study 31701549 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment A
Number of subjects: 0
Study 31701549 — intervention group
Group type: COMPARATOR
Intervention: Treatment B
Number of subjects: 0
Study 31701549 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentile-based bootstrap
Number of subjects: 0
Study 31701549 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal bootstrap
Number of subjects: 0
Study 29273116 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic intervention integrated with family coaching
Number of subjects: 360
Study 29273116 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic intervention alone
Number of subjects: 360
Study 29273116 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 360
Study 26777745 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbial cell preparation (treatment)
Number of subjects: 60
Study 26777745 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 60
Study 23842100 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal FCFD4514S (maximum tolerated dose: 10 mg)
Number of subjects: 18
Study 23842100 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal FCFD4514S
Number of subjects: 18
Study 21732501 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Family Work (IFW)
Number of subjects: 23
Study 21732501 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-family workshops
Number of subjects: 23
Study 20605216 — intervention group
Group type: EXPERIMENTAL
Intervention: Visante optical coherence tomography (OCT) TMH measurement
Number of subjects: 24
Study 20605216 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 24
Study 20605216 — intervention group
Group type: EXPERIMENTAL
Intervention: OCT lower TMH measurement
Number of subjects: 24
Study 18685538 — intervention group
Group type: COMPARATOR
Intervention: Aerobic training (AT) alone
Number of subjects: 72
Study 18685538 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined aerobic training and resistance training (AT/RT1) - 1 set
Number of subjects: 72
Study 18685538 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined aerobic training and resistance training (AT/RT3) - 3 sets
Number of subjects: 72
Study 15639065 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerazette (75-microg desogestrel-only contraceptive pill) taken for 56 days with three tablets taken 12 hours late
Number of subjects: 103
Study 12788993 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive diabetes treatment
Number of subjects: 1229
Study 12788993 — intervention group
Group type: COMPARATOR
Intervention: Conventional diabetes treatment
Number of subjects: 1229
Study 10793299 — intervention group
Group type: EXPERIMENTAL
Intervention: A cocktail of daily doses of 6 g of aged garlic extract, 4-6 g of vitamin C, and 800 to 1200 IU of vitamin E
Number of subjects: 0
Study 10793299 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional antioxidant supplements, hydroxyl radical scavengers, and iron‐binding agents
Number of subjects: 0
Study 8829945 — intervention group
Group type: EXPERIMENTAL
Intervention: Orbicularis oculi response (group 1)
Number of subjects: 120
Study 8829945 — intervention group
Group type: EXPERIMENTAL
Intervention: Adductor pollicis response (group 2)
Number of subjects: 120
Study 8829945 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 min wait (group 3)
Number of subjects: 120
Study 8829945 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 min wait (group 4)
Number of subjects: 120
Study 2072407 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy
Number of subjects: 3538
Study 2072407 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy plus tamoxifen (30 mg daily for 48 weeks)
Number of subjects: 3538
Study 2072407 — intervention group
Group type: COMPARATOR
Intervention: High-risk group not treated with tamoxifen
Number of subjects: 3538
Study 6849755 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg methylprednisolone (Solu‐Medrol)
Number of subjects: 6
Study 6849755 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg naloxone (Nalonee)
Number of subjects: 6
Study 6849755 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 6
Study 31420399 — intervention group
Group type: EXPERIMENTAL
Intervention: SensiumVitals monitoring system (wearable wireless patch)
Number of subjects: 51
Study 27586837 — intervention group
Group type: COMPARATOR
Intervention: Control (1.8 g leucine, n = 7)
Number of subjects: 15
Study 27586837 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucine (3.5 g leucine, n = 8)
Number of subjects: 15
Study 26850813 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyherbal mouthwash (5% v/w)
Number of subjects: 60
Study 26850813 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthwash
Number of subjects: 60
Study 26850813 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthwash
Number of subjects: 60
Study 24182692 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional triamcinolone (T) @40 mg/ml, 1.5 ml, injections every three weeks until complete flattening or eight sessions
Number of subjects: 40
Study 24182692 — intervention group
Group type: COMPARATOR
Intervention: Intralesional verapamil (V) @2.5 mg/ml, 1.5 ml, injections every three weeks until complete flattening or eight sessions
Number of subjects: 40
Study 22524295 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative mood induction (n = 15)
Number of subjects: 30
Study 22524295 — intervention group
Group type: COMPARATOR
Intervention: Neutral mood induction (n = 15)
Number of subjects: 30
Study 22524295 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative mood induction
Number of subjects: 30
Study 20082701 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer simulated heart sounds
Number of subjects: 14
Study 20082701 — intervention group
Group type: COMPARATOR
Intervention: Additional bedside training
Number of subjects: 14
Study 17391154 — intervention group
Group type: EXPERIMENTAL
Intervention: NN344 (0.8, 1.6, 2.8 DU/kg)
Number of subjects: 27
Study 17391154 — intervention group
Group type: COMPARATOR
Intervention: Insulin detemir (0.4, 0.8, 1.4 U/kg)
Number of subjects: 27
Study 17391154 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine (0.4, 0.8, 1.4 U/kg)
Number of subjects: 27
Study 17391154 — intervention group
Group type: EXPERIMENTAL
Intervention: NN344 and insulin detemir
Number of subjects: 27
Study 17391154 — intervention group
Group type: EXPERIMENTAL
Intervention: All insulin preparations
Number of subjects: 27
Study 16331866 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training only (n = 13)
Number of subjects: 43
Study 16331866 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexibility training only (n = 11)
Number of subjects: 43
Study 16331866 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance and flexibility training (n = 9)
Number of subjects: 43
Study 16331866 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group) (n = 10)
Number of subjects: 43
Study 12025879 — intervention group
Group type: EXPERIMENTAL
Intervention: VR group (using head-mounted display and position sensor)
Number of subjects: 30
Study 12025879 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-VR group (no specific details on intervention)
Number of subjects: 30
Study 12025879 — intervention group
Group type: COMPARATOR
Intervention: Control group (received no special treatment)
Number of subjects: 30
Study 11490526 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfamethoxazole-trimethoprim
Number of subjects: 0
Study 11490526 — intervention group
Group type: COMPARATOR
Intervention: Pentamidine isethionate
Number of subjects: 0
Study 7621730 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspiration of insulin syringe during injection
Number of subjects: 204
Study 7621730 — intervention group
Group type: COMPARATOR
Intervention: Non-aspiration technique for insulin administration
Number of subjects: 204
Study 2883055 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile insulin (0.85 mU X kg‐1 X min‐1 during 2 min followed by 8 min with no insulin)
Number of subjects: 6
Study 2883055 — intervention group
Group type: COMPARATOR
Intervention: Continuous insulin (0.17 mU X kg‐1 X min‐1)
Number of subjects: 6
Study 2883055 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile insulin
Number of subjects: 6
Study 29510979 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual-reality group
Number of subjects: 64
Study 29510979 — intervention group
Group type: COMPARATOR
Intervention: Paper-based group
Number of subjects: 64
Study 29510979 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 64
Study 26876240 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined orbital radiotherapy and steroid pulse therapy (SRT group)
Number of subjects: 127
Study 26876240 — intervention group
Group type: COMPARATOR
Intervention: Steroid pulse therapy only (ST group)
Number of subjects: 127
Study 24961903 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiovisual stimuli with different temporal intervals
Number of subjects: 0
Study 24961903 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 0
Study 23135976 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS-guided anaesthesia
Number of subjects: 45
Study 23135976 — intervention group
Group type: COMPARATOR
Intervention: Routine anaesthesia care (non BIS-guided group)
Number of subjects: 45
Study 20551485 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking group (W, n = 14)
Number of subjects: 22
Study 18845407 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens
Number of subjects: 41
Study 18845407 — intervention group
Group type: EXPERIMENTAL
Intervention: Estriol
Number of subjects: 41
Study 18845407 — intervention group
Group type: EXPERIMENTAL
Intervention: Promestriene
Number of subjects: 41
Study 19422676 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (switched from buprenorphine)
Number of subjects: 32
Study 19422676 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (switched from fentanyl)
Number of subjects: 32
Study 15240609 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (10 mg daily)
Number of subjects: 44
Study 15240609 — intervention group
Group type: COMPARATOR
Intervention: Placebo (crossover to Alendronate at 12 months)
Number of subjects: 44
Study 15240609 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 11816513 — intervention group
Group type: EXPERIMENTAL
Intervention: AN69 membranes (Group I)
Number of subjects: 25
Study 11816513 — intervention group
Group type: COMPARATOR
Intervention: Cuprophane membranes (Group II)
Number of subjects: 25
Study 9240727 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg clodronate tablet
Number of subjects: 0
Study 9240727 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg clodronate capsule
Number of subjects: 0
Study 8305996 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed umbilical cord clamping (1 to 2 min)
Number of subjects: 86
Study 8305996 — intervention group
Group type: COMPARATOR
Intervention: Early umbilical cord clamping (immediate after delivery)
Number of subjects: 86
Study 2880804 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 118551, 50 mg t.i.d. orally
Number of subjects: 0
Study 2880804 — intervention group
Group type: COMPARATOR
Intervention: Propranolol, 80 mg t.i.d.
Number of subjects: 0
Study 10657404 — intervention group
Group type: EXPERIMENTAL
Intervention: Selfotel (1.5 mg/kg intravenous dose within 6 hours of stroke onset)
Number of subjects: 567
Study 10657404 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 567
Study 31615192 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor imagery exercises
Number of subjects: 24
Study 31615192 — intervention group
Group type: COMPARATOR
Intervention: Control group (neutral activities)
Number of subjects: 24
Study 29538368 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic (Bifidobacterium longum subsp. infantis CECT7210)
Number of subjects: 190
Study 29538368 — intervention group
Group type: COMPARATOR
Intervention: Control (no probiotic)
Number of subjects: 190
Study 26897029 — intervention group
Group type: EXPERIMENTAL
Intervention: BBaRTS intervention (children's storybooks with embedded BCTs, parenting skills, and oral health messages)
Number of subjects: 2000
Study 26897029 — intervention group
Group type: EXPERIMENTAL
Intervention: BBaRTS intervention supplemented with home supply of fluoride toothpaste (1000 ppmF) and supervised toothbrushing on schooldays
Number of subjects: 2000
Study 26897029 — intervention group
Group type: COMPARATOR
Intervention: Active Control (series of eight books with the same stories, characters, and illustrations but without BCTs, dental health messages, or parenting skills)
Number of subjects: 2000
Study 24469161 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressor septi nasi muscle excision through a transfixion incision
Number of subjects: 100
Study 24469161 — intervention group
Group type: COMPARATOR
Intervention: Depressor septi nasi muscle transposition through an upper labial sulcus incision
Number of subjects: 100
Study 23227315 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher percentage body fat
Number of subjects: 289
Study 23227315 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher fitness
Number of subjects: 289
Study 23227315 — intervention group
Group type: EXPERIMENTAL
Intervention: Fit women categorized as fat
Number of subjects: 289
Study 23227315 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity defined as ≥25 kg/m²
Number of subjects: 289
Study 21060724 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-Loxin(®) 100 mg daily for 90 days
Number of subjects: 60
Study 21060724 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflapin(®) 100 mg daily for 90 days
Number of subjects: 60
Study 21060724 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 17936736 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg hydrocortisone
Number of subjects: 14
Study 17936736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 15167206 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant drinkers consuming 0.1‐19.9 g alcohol per day
Number of subjects: 2710
Study 15167206 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant drinkers consuming 20.0‐39.9 g alcohol per day
Number of subjects: 2710
Study 15167206 — intervention group
Group type: EXPERIMENTAL
Intervention: Female constant drinkers consuming 0.1‐19.9 g daily alcohol
Number of subjects: 2710
Study 12269681 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflexology
Number of subjects: 76
Study 12269681 — intervention group
Group type: COMPARATOR
Intervention: Control (nonspecific foot massage)
Number of subjects: 76
Study 9693202 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg b.i.d. + Amoxicillin 500 mg q.i.d. + Clarithromycin 400 mg b.i.d. (OAC)
Number of subjects: 234
Study 9693202 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg b.i.d. + Clarithromycin 400 mg b.i.d. (OC)
Number of subjects: 234
Study 8207292 — intervention group
Group type: EXPERIMENTAL
Intervention: SY5555 150 mg x 3/day for 7 days
Number of subjects: 38
Study 8207292 — intervention group
Group type: EXPERIMENTAL
Intervention: SY5555 300 mg x 3/day for 7 days
Number of subjects: 38
Study 8207292 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall efficacy for both dosages
Number of subjects: 38
Study 8207292 — intervention group
Group type: EXPERIMENTAL
Intervention: SY5555 150 mg x 3/day
Number of subjects: 38
Study 8207292 — intervention group
Group type: EXPERIMENTAL
Intervention: SY5555 300 mg x 3/day
Number of subjects: 38
Study 8207292 — intervention group
Group type: EXPERIMENTAL
Intervention: SY5555 treatment
Number of subjects: 38
Study 8207292 — intervention group
Group type: EXPERIMENTAL
Intervention: SY5555
Number of subjects: 38
Study 2734323 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (25 mg)
Number of subjects: 14
Study 2734323 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 30292578 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid closed-loop therapy
Number of subjects: 86